What's Happening?
Cresilon Inc., a biotechnology company based in Brooklyn, New York, has announced that its retrospective clinical case series on the use of TRAUMAGEL® in emergency hemorrhagic trauma settings will be featured in a poster presentation at the 2026 Advanced
Trauma Life Support® (ATLS®) Global Symposium. The symposium, hosted by the American College of Surgeons Committee on Trauma, is scheduled to take place from March 13-15 in Birmingham, Alabama. The presentation, titled 'Prehospital Hemorrhage Control Using a Novel Flowable Gel: An Initial Case Series With Traumagel,' will be held on March 14. Cresilon's TRAUMAGEL is a hemostatic medical device that utilizes proprietary hydrogel technology to stop bleeding rapidly. The company aims to advance trauma care through innovation and collaboration, with its products targeting trauma care, biosurgery, and animal health.
Why It's Important?
The inclusion of Cresilon's TRAUMAGEL in the ATLS Global Symposium highlights the potential impact of innovative medical technologies in trauma care. Hemorrhagic trauma is a leading cause of preventable death in emergency settings, and effective hemostatic solutions like TRAUMAGEL could significantly improve survival rates. By showcasing their technology at an international conference, Cresilon is positioned to influence trauma care practices globally. The company's focus on rapid bleeding control aligns with the broader healthcare industry's push for more efficient and effective emergency medical responses. This development could lead to increased adoption of TRAUMAGEL in various medical settings, potentially saving lives and reducing healthcare costs associated with trauma care.
What's Next?
Following the symposium, Cresilon plans to make the poster presentation available on their website, allowing broader access to their findings. The company may seek further collaborations with trauma care professionals and institutions to expand the use of TRAUMAGEL. Additionally, Cresilon's participation in the symposium could lead to new partnerships or investments aimed at enhancing their product offerings and market reach. As the healthcare industry continues to prioritize innovative solutions, Cresilon's technology could see increased interest from both domestic and international markets.
